These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20202603)

  • 1. Doubling back on centromere 17 in early breast cancer.
    Bedard PL; Desmedt C
    Lancet Oncol; 2010 Mar; 11(3):216-7. PubMed ID: 20202603
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
    Bartlett JM; Munro AF; Dunn JA; McConkey C; Jordan S; Twelves CJ; Cameron DA; Thomas J; Campbell FM; Rea DW; Provenzano E; Caldas C; Pharoah P; Hiller L; Earl H; Poole CJ
    Lancet Oncol; 2010 Mar; 11(3):266-74. PubMed ID: 20079691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.
    Slamon DJ; Press MF
    J Natl Cancer Inst; 2009 May; 101(9):615-8. PubMed ID: 19401550
    [No Abstract]   [Full Text] [Related]  

  • 5. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
    Buzdar AU
    J Clin Oncol; 2006 Jun; 24(16):2409-11. PubMed ID: 16682721
    [No Abstract]   [Full Text] [Related]  

  • 6. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
    Rody A; Karn T; Gätje R; Ahr A; Solbach C; Kourtis K; Munnes M; Loibl S; Kissler S; Ruckhäberle E; Holtrich U; von Minckwitz G; Kaufmann M
    Breast; 2007 Feb; 16(1):86-93. PubMed ID: 17010609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma?
    Simon R
    J Clin Oncol; 2011 Jul; 29(21):2941; author reply 2941-4. PubMed ID: 21670460
    [No Abstract]   [Full Text] [Related]  

  • 10. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
    Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
    Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas.
    Bofin AM; Ytterhus B; Hagmar BM
    Cytopathology; 2003 Dec; 14(6):314-9. PubMed ID: 14632728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracyclines, HER2, and TOP2A: the verdict.
    Bonnefoi HR
    Lancet Oncol; 2011 Nov; 12(12):1084-5. PubMed ID: 21917520
    [No Abstract]   [Full Text] [Related]  

  • 13. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
    Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
    Tarpgaard LS; Qvortrup C; Nygård SB; Nielsen SL; Andersen DR; Jensen NF; Stenvang J; Detlefsen S; Brünner N; Pfeiffer P
    BMC Cancer; 2016 Feb; 16():91. PubMed ID: 26867764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
    Pritchard KI
    J Clin Oncol; 2009 Aug; 27(24):3875-6. PubMed ID: 19620479
    [No Abstract]   [Full Text] [Related]  

  • 16. Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells.
    Rondón-Lagos M; Verdun Di Cantogno L; Rangel N; Mele T; Ramírez-Clavijo SR; Scagliotti G; Marchiò C; Sapino A
    BMC Cancer; 2014 Dec; 14():922. PubMed ID: 25481507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifactorial approach to predicting resistance to anthracyclines.
    Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
    J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
    Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
    Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of DNA topoisomerase II alpha in intrinsic and acquired drug resistance of liver cancer].
    Li QY; Wang Y; Yin ZF; Wu FC
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):620-1. PubMed ID: 19719923
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines.
    Azab SS; El-Demerdash E; Abdel-Naim AB; Youssef E; El-Sharkawy N; Osman AM
    Biochem Pharmacol; 2005 Sep; 70(5):725-32. PubMed ID: 16005435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.